Cingulate Therapeutics is a clinical stage biopharmaceutical company based in Morristown, NJ, specializing in the development of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and anxiety associated disorders. With a focus on precision and control, Cingulate is utilizing a novel erosion-based controlled release technology to develop ADHD medications capable of achieving precise once-daily dosing.
With two product candidates, CTX-1301 and CTX-1302, targeting the multi-billion dollar U.S. ADHD market, and a third candidate, CTX-2103, aimed at the U.S. anxiety market, Cingulate is at the forefront of advancing treatments for these neurobiological disorders. Through their Precision Timed Release Platform, which incorporates proprietary erosion barrier layers and specialized compression technology, Cingulate is revolutionizing drug release and delivery, offering new hope for patients and healthcare providers.
Generated from the website